General Updates

Date: September 08, 2026 To To BSE Limited (‘BSE’) National Stock Exchange of India Ltd Listing Department Exchange Plaza, Corporate Relationship Department B a n d r a - Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai 400 051 2nd Floor, Dalal Street, Symbol: MOLBIO Mumbai – 400 001 BSE Script Code: 544866 Subject: Investor Presentation on the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026. Dear Sir/Madam, Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’), please find enclosed herewith a copy of the Investor Presentation or Communication, in connection with the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended June 30, 2026. This presentation will also be available on the Company’s website at www.molbiodiagnostics.com in compliance with Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. You are requested to kindly take the same on record. Thanking You. Yours Faithfully, For Molbio Diagnostics Limited Darshan Raghunath Karekar Company Secretary & Compliance Officer M. No: F13569 Place: Verna-Goa Innovation Led Diagnostic Products Company Investor Presentation Sept’2026 Safe Harbour This presentation and the accompanying slides (the “Presentation”), which has been prepared by Molbio Diagnostics Ltd. (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever . No offering of securities of the Company shall be made except by means of a statutory offering document containing detailed information about the Company . This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation . This Presentation may not be all inclusive and may not contain all the information that you may consider material . Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded . Stakeholders are advised to compare the data provided in the presentation with the full financial results available on the website of the Company as well as on the website of the NSE and BSE . Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward -looking statements . Such forward -looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict . These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world - wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks . The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation . The Company assumes no obligation to update any forward -looking information contained in this Presentation . Any forward -looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections . Management Commentary "FY 27 is a milestone year for Molbio, marking our transition to a listed company . I would like to thank our shareholders, employees, customers and partners for the trust they have placed in Molbio through our recent listing, and we remain committed to delivering on that trust through consistent execution . I am pleased to report that we have begun the year on a strong note, with healthy growth across both revenue and profitability in Q1. However, our business continues to have a non -linear revenue profile, with performance varying across quarters . We therefore believe it is important to assess our performance on a full-year basis . During the quarter, certain export orders pertaining to Q4 FY 26, amounting to approximately ₹57 crore, were deferred due to the prevailing situation in the Gulf and were subsequently recognized in Q1 FY 27. Total Income for Q1 FY 27 stood at ₹411.48 Cr, with EBITDA at ₹103.68 Cr against a loss of ₹14.50 Cr in Q1 FY 26. Growth continues to be led by test-kit consumption across the 12,500 + Truenat ® devices sold in 90 + countries . We entered FY 27 with meaningful capacity headroom - FY 26 device and test-kit utilization at 42 % and 58% , respectively, positioning us for volume -led scale -up without near -term incremental capex . Our pipeline of 34 additional assays across 22 diseases remains on track and will be a key long -term driver as we extend beyond infectious disease into oncology and other non -communicable areas . Internationally, we are deepening our presence across Africa and Southeast Asia, entering Latin Sriram Natarajan America, and progressing regulatory pathways in developed markets, including CE -IVDR for our CTNG Test . Executive Director, and Chief Executive Officer (CEO) Following our listing on August 17, 2026 , deployment of the net issue proceeds is underway across capex for automation and building our R&D facility in Bengaluru . We remain focused on disciplined execution, sustained R&D intensity and improving cash flow quality as our international and acquired businesses scale ." Company & Business Overview Founders’ Journey 1990 -2004 2005 -2018 Sriram Natrajan, co-founded, Tulip Diagnostics Private Bigtec shifts its focus Joint Venture between Sriram Natarajan Limited which later towards chip -based Molbio and Bigtec exited Tulip became one of the PCR (1) research Innovations Private Diagnostics Private largest in -vitro Limited and Bigtec Limited pursuant to diagnostics reagent Private Limited sale to PerkinElmer company in India 2000 2009 2013 2018 1990 2005 2011 2017 Incorporation of Bigtec creates a Launch of the Fully - automatic Molbio Diagnostics ‘lab-on-a-chip ’ semi -automatic PCR (1) device along with its R&D model PCR (1) device "Truelab Uno’ arm Bigtec Labs ‘Truelab Uno’ approved by ICMR (2) Note: (1) Polymerase Chain Reaction (2) Indian Council of Medical Research Journey Post Commercial Launch of Truenat Platform 2019 -2022 2023 onwards • Prognosys 5 received EU MDR certification for the PRORAD radiology systems • Truenat HR-HPV Plus met IARC • Strategic validation criteria in a multicentre study investment in Investment by Investment by • Collaboration with Equine Biotech for OptraSCAN , a Motilal Oswal Temasek Holdings veterinary diagnostics development Digital Pathology Alternate Investment (Private) Ltd (3) Company • US FDA 510(k) clearance for the Advisors Pvt Ltd (2) OptraSCAN System • Launch of EDGE program • Listed on NSE & BSE 2020 2023 2025 2019 2022 2024 2026 • Launch of ICMR (4) Foray in Radiology • EU IVDR Class C approved COVID test ; via Prognosys certification for Truenat ® BioSpectrum product of Medical Systems CT/NG the year award Private Limited • Prognosys 5 received US acquisition • Truenat endorsement FDA 510(k) clearance for by WHO (5) for TB (1) PRORAD ATLAS and ULTRAPORTABLE PLUS Note: (1) For an initial diag [Showing first 8,000 characters — download PDF for full document]